O&O Alpan (United States)

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

Nicola A. Hanania, Oral Alpan, Daniel L. Hamilos et al. · Annals of Internal Medicine · 2011 · 545 citations

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Dominique P. Germain, Derralynn Hughes, Daniel G. Bichet et al. · New England Journal of Medicine · 2016 · 535 citations · Full text

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

Sarbjit S. Saini, Carsten Bindslev‐Jensen, Marcus Maurer et al. · Journal of Investigative Dermatology · 2014 · 449 citations · Full text

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Derralynn Hughes, Suma P. Shankar, Gere Sunder‐Plassmann et al. · Journal of Medical Genetics · 2016 · 370 citations · Full text

Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis

Marc E. Rothenberg, Ting Wen, Allison Greenberg et al. · Journal of Allergy and Clinical Immunology · 2014 · 302 citations

Autoimmune Disease, Allergy, Immunodeficiencies +5